Institute of Clinical and Experimental Medicine

Running trials

• Not yet recruiting

  Efficacy and safety of pharmacological therapy of obesity in liver transplant candidates

  2026-526044-12-00· Phase 4· Institute For Clinical And Experimental Medicine· Source

• Recruiting

  Phase 1b/2 Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIde)

  2025-523010-89-00· Phase 1/2· 35Pharma Inc.· Source

• Recruiting

  Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock

  NCT07583446· Phase 2/3· Seismic Pharmaceuticals Operations LLC· Source

• Recruiting

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  NCT07784725· Phase 3· AstraZeneca· Source

• Recruiting

  Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy

  NCT07424677· Phase 3· Zydus Therapeutics Inc.· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

  NCT07664553· Phase 3· AstraZeneca· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07318597· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

  NCT07365332· Phase 3· Inhibikase Therapeutics· Source

• Recruiting

  Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors

  NCT07536087· Institute for Clinical and Experimental Medicine· Source

• Recruiting

  Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

  NCT07298473· Medtronic Cardiac Ablation Solutions· Source

• Recruiting

  Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure

  NCT07527156· Phase 4· Institute for Clinical and Experimental Medicine· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07351058· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  The effect of semaglutide therapy on hepatic fat content and on the acute response of liver fat to high-fat load

  2023-504988-16-00· Phase 3· Institut Klinicke A Experimentalni Mediciny· Source

• Active, not recruiting

  A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

  NCT07219602· Phase 3· NewAmsterdam Pharma· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· Phase 3· Amgen Inc.· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· Phase 3· Amgen Inc.· Source

• Recruiting

  A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

  2024-518296-56-00· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  2024-513613-12-00· Phase 1/2· Novartis Pharma AG· Source

• Recruiting

  Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation

  NCT06784466· Arga Medtech SA· Source

• Recruiting

  HOPE Against Cancer Recurrence in HCC

  NCT06717919· Phase 4· Philipp Dutkowski· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.

  NCT06832722· Phase 1/2· 4TEEN4 Pharmaceuticals GmbH· Source

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979375· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Recruiting

  Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

  NCT06929806· Phase 3· Pharmacosmos A/S· Source

• Active, not recruiting

  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858878· Phase 3· Amgen· Source

• Active, not recruiting

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· Phase 3· Amgen· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· AstraZeneca· Source

• Recruiting

  Chronic Kidney Disease Screening

  NCT07153432· Institute for Clinical and Experimental Medicine· Source

• Active, not recruiting

  A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

  2024-518343-38-00· Phase 3· Alnylam Pharmaceuticals Inc.· Source

• Recruiting

  Closed-loop in Adults With Type 2 Diabetes

  NCT06579404· University of Cambridge· Source

• Recruiting

  Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening

  NCT06549725· Lipidica, a.s.· Source

• Recruiting

  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

  NCT06274801· Phase 3· Gossamer Bio USA, Inc.· Source

• Recruiting

  Mechanisms of Pulmonary Vascular Dysfunction in Heart Failure

  NCT06331208· Institute for Clinical and Experimental Medicine· Source

• Active, not recruiting

  Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

  NCT06492291· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  The Role of Sugars in Fat Accumulation in the Liver

  NCT06751862· Institute for Clinical and Experimental Medicine· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Grafalon®therapy within 12 weeks of Type 1 diabetes (T1D) diagnosis in children and young adults to prevent the loss of residual beta cell function: a randomised, double-blind, placebo-controlled dose finding study Acronym: GIRO T1D

  2023-508514-42-00· Phase 2· Institute For Clinical And Experimental Medicine· Source

• Active, not recruiting

  Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

  NCT06291376· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· Phase 3· AstraZeneca· Source

• Recruiting

  A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

  NCT05646381· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

  NCT06059638· Orchestra BioMed, Inc· Source

Showing 50 of 69.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure13 recruiting
• High blood pressure7 recruiting
• Obesity7 recruiting
• Pulmonary arterial hypertension5 recruiting
• Type 2 diabetes5 recruiting
• Atrial fibrillation4 recruiting
• Type 1 diabetes4 recruiting
• Coronary artery disease3 recruiting
• Crohn's disease3 recruiting
• Amyloidosis2 recruiting
• Chronic kidney disease2 recruiting
• Gastroparesis2 recruiting
• Pancreatic cancer2 recruiting
• Primary biliary cholangitis2 recruiting
• ANCA-associated vasculitis1 recruiting
• Aortic stenosis1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and oesophageal cancer1 recruiting
• IgA nephropathy1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Myocarditis1 recruiting
• Neuroendocrine tumours1 recruiting
• Ulcerative colitis1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  An Open-Label Extension Study for Participants with PAH Who Have Previously Participated in a Clinical Trial with PF-07868489

  2025-521155-23-00· Phase 2· Pfizer Inc.· Source

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· Phase 3· Ipsen· Source

• Completed

  A proof of concept and dose-finding study of XXB750 in patients with heart failure

  2023-504678-39-00· Phase 2· Novartis Pharma AG· Source

• Completed

  A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

  NCT06269484· Phase 2· AstraZeneca· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Completed

  Early Detection of HCV in Injection Drug Users

  NCT06431945· Institute of Health Information and Statistics of the Czech Republic· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

  NCT06137742· Phase 1/2· Pfizer· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

  NCT05813912· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

  NCT05952869· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Pulsed-field Ablation in Patients With Persistent Atrial Fibrillation

  NCT05922917· České Budějovice Hospital· Source

• Completed

  A Phase 2 Study of the Effects of Ponsegromab on Health-Related Quality of Life and Safety in Patients With Heart Failure (GARDEN-TIMI 74)

  NCT05492500· Phase 2· Pfizer Inc.· Source

• Completed

  A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

  NCT05737940· Phase 2· AstraZeneca· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Myokardia Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

  2024-517612-29-00· Phase 4· The Brigham And Women’s Hospital Inc.· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Abivax S.A.· Source

• Completed

  Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

  NCT05669599· Phase 2· Amgen· Source

• Completed

  A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

  NCT05646706· Phase 3· Novo Nordisk A/S· Source

• Completed

  Gluten-free Diet in PSC and IBD

  NCT06026449· Institute for Clinical and Experimental Medicine· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  Ground-Breaking Electroporation-based Intervention for PERSistent Atrial Fibrillation Treatment (BEAT PERS-AF)

  NCT05418725· University Hospital, Bordeaux· Source

• Completed

  Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction

  NCT05350969· Phase 2· Cardior Pharmaceuticals GmbH· Source

• Completed

  A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients.

  NCT04811092· Phase 3· Acceleron Pharma Inc.· Source

• Completed

  Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts

  NCT05369975· Phase 3· Hansa Biopharma AB· Source

• Completed

  A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents and adults that have recently been diagnosed type 1 diabetes. The safety of Diamyd will also be investigated. Some subjects may receive a placebo drug.

  NCT05018585· Phase 3· Diamyd Medical AB· Source

• Completed

  Ground-Breaking Electroporation-based Intervention for PAROXysmal Atrial Fibrillation Treatment (BEAT PAROX-AF)

  NCT05159492· University Hospital, Bordeaux· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

  NCT05013229· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

  NCT05093933· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Long-term Follow-up Study of Sotatercept for PAH Treatment

  NCT04796337· Phase 3· Acceleron Pharma Inc.· Source

• Completed

  A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

  NCT04560998· Phase 3· Novo Nordisk A/S· Source

• Completed

  STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease

  NCT04612140· University Hospital Ostrava· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Bayer· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Completed

  APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

  NCT03997383· Phase 3· Alnylam Pharmaceuticals· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

  NCT03811561· Phase 3· Novo Nordisk A/S· Source

• Completed

  Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease

  2024-511553-22-00· Phase 3· Celgene International II SARL· Source

• Completed

  Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease

  2023-510426-33-00· Phase 3· Celgene International II S.a.r.l.· Source

• Completed

  A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

  NCT03723655· Phase 2/3· Bristol-Myers Squibb· Source

• Completed

  DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation

  NCT03643224· Medtronic Cardiac Ablation Solutions· Source

• Completed

  Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction

  NCT03551964· Phase 4· Faculty Hospital Kralovske Vinohrady· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Shire· Source

• Completed

  An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

  NCT02531126· Phase 3· Celgene· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Ventricular tachycardia13 works · 2 trials